Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients

Stopped early · Phase 4

Conditions studied: Anxiety, Pediatric ALL, Procedural Anxiety

In brief

Investigators plan to conduct a randomized, double-blinded, controlled study among pediatric patients requiring minor procedures in the Emergency Department setting. Patients will be randomized to one of two arms of intranasal treatments: ketamine 1.0 mg/kg (K) or midazolam 0.3 mg/kg (M). The primary outcome will be change in anxiety using the Modified Yale Preoperative Anxiety Scale (mYPAS).

Key facts

Study ID
NCT03043430
Run by
Brooke Army Medical Center
People needed
10
Starts
2016-05-01
Expected to finish
2023-04-01
Last updated by the study team
2023-04-25

Who can join

Age: 2 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.